Evergreen Nephrology Posts Strong CMS Savings While Doubling Down on Patient Education and Physician Ties

Evergreen Nephrology continued to spotlight its value-based kidney care strategy this week, emphasizing patient education, strong government program results, and expanded physician engagement. The company underscored its partnership-driven model with nephrologists as a core differentiator in a competitive kidney care landscape.

Evergreen reported standout 2024 performance in the CMS Kidney Care Choices program, generating more than $40 million in Medicare savings and ranking second nationally among Kidney Contracting Entities in net savings. Partnered provider organizations represented three of the top 10 performers, reinforcing the effectiveness of Evergreen’s tools, data, and care coordination.

The company disclosed that its model produced roughly $225 in Medicare savings per patient per month and supported over $35 million in performance payments tied to care quality. Evergreen achieved a 2.3% net shared savings rate, with total program payouts rising 24% year over year, suggesting increased scale and consistent execution across its network.

Clinically, Evergreen highlighted a 58% optimal start rate for kidney replacement therapy, delayed progression to kidney failure in 35% of a tracked stage 4 chronic kidney disease cohort, and a 25% higher transplant access rate than the national average. Management framed these outcomes as evidence that early intervention and coordinated care can align quality improvement with predictable shared savings.

In parallel, Evergreen used multiple communications to stress patient education as a central pillar of its care model. The company described high-touch support that includes answering questions, clarifying medications, assisting with symptom management, and connecting patients to social and emotional resources to improve engagement and adherence.

This education-first approach is designed to work alongside nephrologists to help patients better understand their condition and treatment options, potentially reducing hospitalizations and supporting value-based reimbursement outcomes. If maintained, such a model could strengthen Evergreen’s positioning with payors and health systems seeking partners able to manage total cost of care in advanced kidney disease.

Evergreen also emphasized relationship-building with physicians at the RPA 2026 conference in Atlanta, hosting an evening event and maintaining a presence on the exhibit floor. These activities aim to deepen ties with nephrologists, support referral networks, and expand the company’s footprint across value-based kidney care arrangements.

Overall, the week’s developments point to Evergreen Nephrology consolidating its role as a leading outcomes-focused, value-based kidney care platform, combining strong CMS performance, intensive patient support, and growing physician partnerships to support its long-term growth prospects.